Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease
Shots:
- Innovent has reported results from the P-III of P-II/III (RESTORE-1) study assessing the safety and efficacy of IBI311 vs PBO to treat thyroid eye disease (TED) in China, for which the company anticipates NDA submission to the NMPA
- The P-III of the trial demonstrated a proptosis responder rate (1EP) of 85.8% vs 3.8% at wk. 24 with a difference of 81.9% and met the 2EPs incl. ORR, percentage of patients with a clinical activity score (CAS) of 0 or 1 and mean change in proptosis from baseline in the study eye
- IBI311, recombinant anti-IGF-1R Ab, targets the IGF-1R signaling pathway to prevent the downstream expression of inflammatory factors thus reducing the disease activity of TED patients
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
